Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: Prospective validation of the SYNTAX Score II

European Heart Journal

Volumn 36, Issue 20, 2015, Pages 1231-1241

  Campos, Carlos M ^a,b   Van Klaveren, David ^a   Farooq, Vasim ^c   Simonton, Charles A ^d   Kappetein, Arie Pieter ^a   Sabik, Joseph F ^e   Steyerberg, Ewout W ^a   Stone, Gregg W ^f,g   Serruys, Patrick W ^a,h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d ABBOTT VASCULAR   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary artery bypass surgery; Drug eluting stents; Left main; Mortality; Percutaneous coronary intervention; SYNTAX score; SYNTAX Score II

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG EFFICACY; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FORECASTING; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; LEFT CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SYNTAX SCORE; TREATMENT OUTCOME; UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE; UNPROTECTED LEFT-MAIN CORONARY ARTERY DISEASE; VALIDATION STUDY; CLINICAL DECISION SUPPORT SYSTEM; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

AGED; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASES; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84929739277     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu518     Document Type: Article

References (33)

1. Favaloro RG. Saphenous vein autograft replacement of severe segmental coronary artery occlusion: operative technique. Ann Thorac Surg 1968; 5: 334-339
2. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570
3. Taggart DP. Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. Ann Thorac Surg 2006; 82: 1966-1975
4. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronaryartery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61-68
5. Farooq V, SerruysPW, StoneGW, Virmani R, Chieffo A, Fajadet J. Percutaneous interventional cardiovascular medicine. Left main coronary artery disease. The PCR-EAPCI Textbook. EUROPA edn. Toulouse, France: PCR Publishing; 2012. pp. 329-405
6. Al Ali J, Franck C, Filion KB, Eisenberg MJ. Coronary artery bypass graft surgery versus percutaneous coronary intervention with first-generation drug-eluting stents: a meta-Analysis of randomized controlled trials. JACC Cardiovasc Interv 2014; 7: 497-506
7. Athappan G, Patvardhan E, Tuzcu ME, Ellis S, Whitlow P, Kapadia SR. Left main coronary artery stenosis: a meta-Analysis of drug-eluting stents versus coronary artery bypass grafting. JACC Cardiovasc Interv 2013; 6: 1219-1230
8. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, WijnsW, Witkowski A, Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: TheTask ForceonMyocardialRevascularizationof the EuropeanSocietyofCardiology (ESC) and the EuropeanAssociation forCardio-Thoracic Surgery (EACTS)Developed with the special contribution of the EuropeanAssociation of PercutaneousCardiovascular Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619
9. Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS Paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with De novo native coronary artery lesions). JACC Cardiovasc Interv 2013; 6: 1263-1266
10. Brener SJ, Kereiakes DJ, Simonton CA, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Smith RS Jr, Ying SW, Cutlip DE, Stone GW. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions trial. Am Heart J 2013; 166: 1035-1042
11. StoneGW, Rizvi A, NewmanW, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ, Investigators SI. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-1674
12. Kedhi E, Joesoef KS, McFadden E, Wassing J, Van Mieghem C, Goedhart D, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-209
13. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, NewmanW, Sudhir K, Smith RS Jr, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW. Meta-Analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6: 914-922
14. Farooq V, Van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR Jr, Mack M, Feldman T, Morice MC, Stahle E, Onuma Y, Morel MA, Garcia-Garcia HM, Van Es GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013; 381: 639-650
15. Farooq V, Van Klaveren D, Steyerberg EW, SerruysPW. SYNTAXscore II - authors' reply. Lancet 2013; 381: 1899-1900
16. Campos CM, Van Klaveren D, Iqbal J, Onuma Y, Zhang YJ, Garcia-Garcia HM, Morel MA, Farooq V, Shiomi H, Furukawa Y, Nakagawa Y, Kadota K, Lemos PA, Kimura T, Steyerberg EW, Serruys PW. Predictive performance of SYNTAX Score II in patients with left main and multivessel coronary artery disease. Circ J 2014; 78: 1942-1949
17. SerruysPW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stahle E, Feldman TE, Van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW, Investigators S. Percutaneous coronary intervention versus coronaryartery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972
18. Zhang YJ, Iqbal J, Campos CM, KlaverenDV, BourantasCV, Dawkins KD, BanningAP, Escaned J, De Vries T, Morel MA, Farooq V, Onuma Y, Garcia-Garcia HM, StoneGW, SteyerbergEW, MohrFW, SerruysPW. Prognostic value of site SYNTAXscore and rationale for combining anatomic and clinical factors in decision making: insights from the SYNTAX trial. J Am Coll Cardiol 2014; 64: 423-432
19. Stef Van Buuren KG-O. Multivariate imputation by chained equations in R. J Stat Softw 2011; 45; 1-67
20. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Taylor & Francis; 1994
21. MohrFW, MoriceMC, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR Jr, Morel MA, Van Dyck N, Houle VM, Dawkins KD, Serruys PW. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629-638
22. Farooq V, Serruys PW, Bourantas C, Vranckx P, Diletti R, Garcia Garcia HM, Holmes DR, Kappetein AP, Mack M, Feldman T, Morice MC, Colombo A, Morel MA, De Vries T, Van Es GA, Steyerberg EW, Dawkins KD, Mohr FW, James S, Stahle E. Incidence and multivariable correlates of long-Term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. Eur Heart J 2012; 33: 3105-3113
23. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: the R Foundation for Statistical Computing; 2005
24. Morice MC, SerruysPW, Kappetein AP, Feldman TE, Stahle E, Colombo A, Mack MJ, Holmes DR, Choi JW, Ruzyllo W, Religa G, Huang J, Roy K, Dawkins KD, Mohr F. Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. Circulation 2014; 129: 2388-2394
25. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, Holmes DR, Mack M, Morice MC, Stahle E, Colombo A, De Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013; 128: 141-151
26. Généreux P, Campos CM, Yadav M, Palmerini T, Caixeta A, Xu K, Francese DP, Dangas GD, Mehran R, Leon MB, Serruys PW, Stone GW. Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index. EuroIntervention 2014; doi: 10.4244/EIJY14M10-05
27. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S III, Bertrand M, Fuster V, Investigators FT. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375-2384
28. Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR, Alberta Kidney Disease N. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380: 807-814
29. Mahmoodi BK, Matsushita K, Woodward M, Blankestijn PJ, Cirillo M, Ohkubo T, Rossing P, Sarnak MJ, Stengel B, Yamagishi K, Yamashita K, Zhang L, Coresh J, De Jong PE, Astor BC, Chronic Kidney Disease Prognosis C. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-Analysis. Lancet 2012; 380: 1649-1661
30. Capodanno D, Capranzano P, La Manna A, Tamburino C. Meta-Analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention. Int J Cardiol 2013; 168: 1718-1719
31. MoynaghA, Salvatella N, Harb T, Darremont O, Boudou N, Dumonteil N, LefevreT, Carrie D, Louvard Y, Leymarie JL, Chevalier B, Morice MC, Garot P. Two-year outcomes of everolimus vs. paclitaxel-eluting stent for the treatment of unprotected left main lesions: a propensity score matching comparison of patients included in the French Left Main Taxus (FLM Taxus) and the LEft MAin Xience (LEMAX) registries. EuroIntervention 2013; 9: 452-462
32. FarooqV, SerruysPW. Complex coronary artery disease: would outcomes from the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) trial have differed with newer-generation drug-eluting stents?JACC Cardiovasc Interv 2013; 6: 1023-1025
33. FarooqV, SerruysPW, ZhangY, MackM, Stahle E, HolmesDR, FeldmanT, MoriceMC, Colombo A, Bourantas CV, De Vries T, Morel MA, Dawkins KD, Kappetein AP, Mohr FW. Short-Term and long-Termclinical impact of stent thrombosis and graft occlusion in the SYNTAXtrial at 5 years: synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. J AmColl Cardiol 2013; 62: 2360-2369